Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New lipid-modifying therapies.

Eric Bruckert1

  • 1Department of Endocrinology & Metabolism, Assitance-Publique Hôpitaux de Paris, University Hôp[ital Pitie-Salpêtrière, Paris, France. eric.bruckert@psl.ap-hop-paris.fr

Expert Opinion on Investigational Drugs
|February 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.

Atherosclerosis·2026
Same author

Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial.

The lancet. Diabetes & endocrinology·2026
Same author

Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.

Molecular metabolism·2025
Same author

Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary.

Future cardiology·2025
Same author

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.

Circulation·2025
Same author

Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions.

Archives of medical science : AMS·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Lipid abnormalities increase cardiovascular disease risk. New statins, drug formulations, and novel agents like cholesterol absorption inhibitors offer improved lipid management and cardiovascular disease prevention strategies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Lipid abnormalities are key risk factors for cardiovascular disease (CVD).
  • Effective lipid management is crucial for CVD prevention.
  • Current therapies aim to normalize lipid profiles and reduce CVD incidence.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for managing lipid abnormalities.
  • To highlight advancements in lipid-modifying agents and their mechanisms of action.
  • To discuss the potential of combination therapies and novel drug targets for dyslipidemia.

Main Methods:

  • Review of current literature on lipid-modifying therapies.
  • Analysis of the efficacy and tolerability of established and novel lipid-lowering drugs.

Related Experiment Videos

  • Exploration of emerging therapeutic targets and experimental approaches in dyslipidemia management.

    • Main Results:

    • Statins, particularly newer agents like rosuvastatin, are effective in lowering low-density lipoprotein cholesterol.
    • Improved drug formulations (e.g., nicotinic acid) enhance patient compliance.
    • Novel agents, including cholesterol absorption inhibitors (ezetimibe) and acyl-coenzyme A cholesterol acyltransferase inhibitors (avasimibe), offer new therapeutic pathways.
    • Combination therapy with statins shows potential for greater lipid profile improvements.
    • Advances in understanding dyslipidemia pathophysiology reveal new therapeutic targets.

    Conclusions:

    • The landscape of lipid management is evolving with more effective and tolerable therapies.
    • Novel agents and combination strategies hold promise for enhanced cardiovascular disease risk reduction.
    • Continued research into dyslipidemia pathophysiology will likely yield further therapeutic innovations.